[PDF] Escherichia coli multi-résistant, producteur d`une carbapénémase - Rapport Annuel

What is the global molecular epidemiology of 229 carbapenemase-producing Escherichia coli?

We describe the global molecular epidemiology of 229 carbapenemase-producing Escherichia coli in 36 countries during 2015–2017. Common carbapenemases were oxacillinase (OXA) 181 (23%), New Delhi metallo-?-lactamase (NDM) 5 (20%), OXA-48 (17%), Klebsiella pneumoniae carbapenemase 2 (15%), and NDM-1 (10%).

What is carbapenem-resistant Escherichia coli (Creco)?

Carbapenem-resistant Escherichia coli (CREco) is currently one of the main pathogens of CRE causing various clinical infections [ 5, 6 ]. According to a statistical result of CDC in the United States, the proportion of CREco was only 0.9% from 2006 to 2007, but it increased to 1.9% from 2009 to 2010 [ 1, 7 ].

Which phylogroup is first in abundance in clinical carbapenemase-producing E coli causing extraintestinal infections?

In conclusion, in this study, we provide insight into the diversity of phylogroups, clones, subclones, serotypes, and resistance and virulence genes in clinical carbapenemase-producing E. coli causing extraintestinal infections. Specifically, we found CC10 to be first in abundance instead of ST131.

Is plasmid characterization necessary to understand global carbapenemase-producing E coli?

The characterization of plasmids is vital to fully comprehend the molecular epidemiology of global carbapenemase-producing E. coli, and a follow-up study using long-read sequencing is under way.